8 results about "Viral hepatitis" patented technology

To provide novel agents for the treatment or prevention of Epstein-Barr virus hepatitis. [Solution] A pharmaceutical composition for the treatment or prevention of Epstein-Barr virus hepatitis in a subject, comprising ibudilast, dipyridamole, or both as active ingredients.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation and / or fibrosis in the liver, e.g., metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), primary biliary cholangitis, primary sclerosing cholangitis, alcoholic cirrhosis, hepatitis cirrhosis, cholestasis, autoimmune hepatitis, viral hepatitis B, viral hepatitis C, hemochromatosis, Wilson's disease, or alcoholic steatohepatitis, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

The invention discloses a preparation method of alpha-ketoisovaleric acid in an anti-hepatic fibrosis drug, and relates to the technical field of hepatic fibrosis treatment drug development, and the preparation method comprises the following steps: mixing alpha-ketoisovaleric acid with pharmaceutic adjuvants to prepare a pharmaceutically acceptable dosage form; the dosage of the alpha-ketoisovaleric acid is determined based on the pharmacological activity of the alpha-ketoisovaleric acid in the concentration range of 50 mu M to 200 mu M, wherein the alpha-ketoisovaleric acid can inhibit hepatic stellate cell activation induced by a transforming growth factor-beta; an endogenous metabolite alpha-ketoisovaleric acid is applied to preparation of an anti-hepatic fibrosis medicine, and based on the pharmacological activity of the alpha-ketoisovaleric acid for specifically inhibiting activation of TGF-beta induced hepatic stellate cells at the concentration of 50-200 mu M, a novel anti-hepatic fibrosis preparation which is high in safety, wide in therapeutic window and free of liver and kidney accumulation risk is developed. The medicine is not only suitable for treating hepatic fibrosis caused by various causes such as non-alcoholic fatty liver disease, viral hepatitis, alcoholic liver disease and drug-induced liver injury, but also meets the requirements of early intervention and severe treatment through reasonable dosage form design and administration route selection.

This invention relates to a novel use of synephrine in the preparation of drugs for treating cholestatic liver disease, belonging to the field of pharmaceutical technology. Cholestatic liver disease is characterized by jaundice and conjugated bilirubin and / or total bilirubin hyperconjugation caused by impaired bilirubin excretion due to various reasons. Its causes include common bile duct stones, pancreatic duct cancer, common bile duct malignant tumors, pancreatic cancer, biliary parasitic diseases, viral hepatitis cirrhosis, alcoholic liver disease, fatty liver disease, drug-induced liver injury, primary biliary cirrhosis, intrahepatic sclerosing cholangitis, and certain congenital diseases such as Dubin-Johnson syndrome and Rotor syndrome. This invention establishes a mouse cholestasis model using bile duct ligation and administers synephrine by gavage to evaluate its protective effect against liver injury. The results showed that synephrine significantly improved jaundice caused by cholestasis, reduced hepatocellular necrosis and inflammatory infiltration caused by cholestasis, alleviated bile duct dilation, decreased serum total bilirubin (TBIL) and direct bilirubin (DBIL), and reduced the levels of total bile acids (BA) in liver tissue and plasma. Furthermore, the above-mentioned effects of synephrine in improving cholestasis showed a clear dose-dependent effect. This invention reveals for the first time the application of synephrine in cholestatic liver disease, demonstrating good safety and promising clinical development prospects.

The invention discloses an application of alzovudine in resisting viral hepatitis B, and belongs to the technical field of medicine application. The alzovudine is used for treating and resisting viral hepatitis B. An in-vivo and in-vitro combined efficacy verification system is established, a multi-genotype and drug-resistant mutation HBV model is covered, experimental results are stable and repeatable, and screening and evaluation of novel nucleoside anti-HBV drugs can be effectively guided. The invention reveals that the FNC has the comprehensive technical advantages of broad-spectrum virus resistance, drug-resistant mutation resistance, strong antigen removal capability, high safety and the like in the treatment of hepatitis B virus infection, breaks through the bottleneck that the existing NAs has limited curative effect and the antigen is difficult to remove, and provides a new candidate drug and a technical route for functional cure of chronic hepatitis B.

The invention discloses an application of a fortune euonymus herb chemical fiber formula in treatment of hepatic fibrosis, and relates to the field of biological medicines. According to the present invention, the anti-hepatic fibrosis effect is provided by inhibiting hepatic stellate cell activation and reducing extracellular matrix deposition, and the hepatic fibrosis is the chronic liver injury pathological stage caused by viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease or drug-induced liver injury; in an in-vitro experiment, the euonymus fortunei chemical fiber formula also plays a role in resisting hepatic fibrosis by inhibiting a transient receptor potential vanillic acid subtype 4 signal channel. The method has the following comprehensive advantages that (1) HSC activation and ECM deposition are inhibited through multi-component and multi-target cooperation; (2) key signal channels such as TGF-beta1 / Smad, TRPV4 and the like can be regulated and controlled at the same time; (3) liver function indexes are obviously improved, and tissue structure damage is relieved; and (4) the medicine is natural in source, high in safety and suitable for long-term application.

The present application provides a composition for treating hepatitis C and a preparation method thereof. The composition comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The composition or capsule can effectively treat hepatitis C, and the preparation process is simple, safe, stable, and has rapid dissolution.

The invention discloses a prediction method for differential diagnosis of autoimmune hepatitis based on ASGPR and a related product thereof, and relates to the field of biological diagnosis. The invention provides a novel marker which can be used for evaluating the risk of the autoimmune hepatitis of a subject, so that the detection sensitivity and specificity of the autoimmune hepatitis can be remarkably improved, and the missed diagnosis and misdiagnosis rates are effectively reduced; effective identification of AIH and other liver diseases (such as viral hepatitis, drug-induced liver injury, metabolic fatty liver and the like) or healthy people can be realized, and a detection kit or a prediction method developed based on the marker has the advantages of simplicity and convenience in operation, high flux and controllable cost, is easy to popularize in clinical practice and has a wide application prospect. Therefore, the early discovery rate of the autoimmune hepatitis and the timeliness of treatment intervention are greatly improved.